A new study in Clinical Epidemiology and Global Health features the Glivec^®Patient Assistance Program (GIPAP) and reveals that “chronic myelocytic leukemia (CML) is diagnosed at an earlier age in poorer populations than in more affluent populations.” The study focused on India’s CML population to investigate other possible contributors to early age at onset. The team of authors include our very own South Asia Region Head Viji Venkatesh, and Max CEO Pat Garcia-Gonzalez, as well as Paul H. Levine, Kunal Ajmera, Brenna O’Neill, Heather J. Hoffman.

The study is only available to the public for a limited time so if you know a physician or researcher that would benefit from this study, share it today!